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Abstract
Background: Adolescents with DMD treated with chronic high dose GC therapy typically have profound pubertal
delay. Testosterone, the main circulating androgen in men, promotes virilisation and growth with associated accrual
of fat-free muscle mass and bone mineral content. Testosterone therapy is routinely used to mimic the normal
stages of pubertal development in patients with hypogonadotrophic hypogonadism, androgen deficiency
secondary to testicular disease and in constitutional delay of growth and puberty (CDGP). Improved life expectancy
in DMD has meant that more adolescents are eligible for testosterone supplementation but there is little objective
data regarding the impact of this treatment on muscle structure and function, bone integrity and overall well-
being.
Methods: This is a single centre observational clinical trial (NCT02571205) that aims to follow the progress of 15
adolescents with Duchenne muscular dystrophy and delayed puberty as they are managed with incremental
testosterone therapy to induce puberty. Subjects will all be treated with a steadily increasing dose of testosterone
administered by injection every 4 weeks and data will be collected to help us determine the effectiveness and
tolerability of the described treatment regimen. We will use the data to explore the effects of testosterone on
pubertal development, growth, muscle strength and function, bone mineral density, body composition with a
detailed record of any adverse events. We will also carry out interviews to explore the boys’ views on the
tolerability of the regimen. The study will last for 27 months in total for each participant.
Discussion: Our experience has indicated that testosterone treatment in adolescents with DMD is liked and well
tolerated but we have not collected objective data on a specific treatment regimen and there is no current
consensus. Testosterone supplementation is not part of the standard of care of pubertal delay in DMD but inclusion
in future protocols may be appropriate depending on the results of this trial.
Trial registration: EudraCT Number: 2015–003195-68. Research Registry & References: Clinical trials.gov-
NCT02571205 (registered 8/10/15).
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Background
Duchenne muscular dystrophy (DMD) is a severe and
ultimately fatal, X-linked genetic disease that affects up
to 1 in 3500 live male births [1]. DMD occurs as a result
of mutations in the gene at 21p on the X chromosome
with an associated reduction or complete loss of dys-
trophin protein. DMD is the most common muscular
dystrophy in childhood and is associated with progres-
sive muscle weakness. Untreated individuals lose ambu-
lation by a mean age of 9.5 years [2]. Respiratory, cardiac
or orthopaedic complications usually cause premature
death in the second or third decade [3]. Whilst there is
still no cure for DMD, therapeutic advances such as the
routine use of glucocorticoids (GC) and co-ordinated
multidisciplinary care have dramatically improved the
course of the disease [4]. Patients with DMD now regu-
larly survive into their thirties [5]. GC are the key treat-
ment in DMD and are the only medical therapy proven
to stabilise muscle strength for a limited period [6]. Con-
tinuing longitudinal follow-up of steroid-treated cohorts
has found that long-term, regular use of GC is associ-
ated with improved muscle strength and 3 additional
years of independent ambulation with preserved upper
limb function [7]. In addition GC improve and maintain
respiratory function [8], delay the development of ortho-
paedic complications [9] (e.g. scoliosis) and may have a
positive impact on cardiac function [10]. Unfortunately
the use of GC in DMD is associated with frequent and
substantial side-effects that are a major issue for many
patients. A range of organ systems are affected with
growth retardation [11], impaired bone mineralisation
(increasing risk of vertebral and lower limb fractures
[12]), impaired glucose metabolism, cataracts [13], ad-
renal suppression, and pubertal delay.
Pubertal delay is one of the main concerns reported by
adolescents with DMD on long-term treatment with
high dose GC and is an almost universal finding. GC in-
hibit the production of factors regulating the
hypothalamic-pituitary axis during puberty resulting in
hypogonadotrophic hypogonadism. One study showed
that by 11.5 +/− 2.9 years of age, 97% of boys were
pre-pubertal with an average height z-score of − 2.9 [14].
Similarly, 43/44 GC-treated boys in an American DMD
cohort were pre-pubertal at 13 years of age or older [15].
Delayed puberty may have a number of detrimental ef-
fects. Adverse psychosocial and educational conse-
quences of failure to advance through puberty are well
recognised and adolescents with DMD get frustrated as
people often think they are younger than they are. For
some parents the psychosocial stress associated with the
disorder and its treatment exceeds that caused by the
physical aspects of the condition [16]. A study of sub-
cutaneous testosterone therapy in 18 adolescents with
primary hypogonadism demonstrated an improvement
in psychosocial outlook and self-image [17]. This is con-
sistent with reports of increased cheerfulness and relax-
ation in hypogonadal men receiving androgen
replacement [18, 19]. In some studies the mean age of
initiation of androgen therapy is well after a point at
which normal pubertal development is typicallyy ob-
served [20]. Pubertal delay is often associated with sig-
nificant emotional distress and so this delay should be
avoided.
The delayed puberty and lack of an associated pubertal
growth spurt coupled with the short stature associated
with DMD means that by adolescence almost all those
with DMD are very short and look much younger than
their age. As the standards of care have changed and
health of adolescents with DMD has improved, the ex-
pectations of the patients have also changed with more
young people seeking to establish relationships and to
lead independent adult lives.
As a result, we face new challenges in the follow-up
and supportive care of those with DMD. Families are in-
creasingly seeking an endocrine specialist opinion to dis-
cuss possible treatment options for short stature and
pubertal delay. This is not a straightforward consultation
due to the likely multifactorial nature of the growth fail-
ure and pubertal delay and the need to consider con-
comitant GC use and potential side effects.
Rationale for the study
Testosterone is the main circulating androgen in men
and promotes virilisation and growth with associated ac-
crual of fat-free muscle mass and bone mineral content.
Testosterone levels of up to 30 times greater than those
found during childhood are required to initiate and
maintain puberty. Testosterone supplementation is
routinely used to mimic the normal stages of pubertal
development in patients with hypogonadotrophic hypo-
gonadism, androgen deficiency secondary to testicular
disease and in constitutional delay of growth and
puberty (CDGP). However, DMD is a rare disease and
testosterone therapy has only been given in recent years
as life-expectancy has improved. There are very few data
regarding the benefit of testosterone treatment in DMD,
especially in relation to muscle and bone. A recent local
audit of the 14 adolescents with DMD treated with
testosterone for pubertal delay found that there was
some height gain but the usual growth increment from
puberty was compromised [21]. Few had adult levels
of endogenous testosterone levels at the end of the
study period despite being on treatment for over 4
years in some cases, suggesting that sub-optimal
treatment regimens may have been used or that the
hypothalamic-pituitary axis remains suppressed with
ongoing GC use.
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Testosterone is currently only offered to a minority of
adolescents with DMD based on the experience and ex-
pertise of the clinician involved in patient care. Limited
evidence suggests that testosterone is a useful and
well-liked adjuvant therapy that can help address two of
the boy’s main concerns which are short stature and pu-
bertal delay. There is, therefore, a clear need for a study
to systematically evaluate treatment satisfaction and effi-
cacy of testosterone in DMD adolescents with pubertal
delay. There is a need to confirm and evaluate the effect
of testosterone on key outcomes such as testicular vol-
ume, bone strength, growth and muscle function. There
is also lack of information regarding the impact of tes-
tosterone replacement therapy on overall quality of life
in this population. It is becoming increasingly acknowl-
edged that the patient’s experience of health is vitally im-
portant. We have decided to employ a mixed methods
approach for the primary outcome measure. As well as
routine clinical outcome measures, we will also carry
out qualitative interviews on a subset of the population
studied to gauge their ideas, concerns and expectations
in more depth.
Trial objectives
Primary
 Evaluate patient satisfaction in response to
testosterone replacement therapy in patients with
DMD and pubertal delay
Secondary
 Evaluate the effect of an incremental regimen of
intramuscular testosterone therapy on pubertal
staging, testicular volume and sex hormone levels
 Evaluate the effect of testosterone supplementation
on growth
 Evaluate the effect of testosterone replacement
therapy on muscle strength, mass and function
 Evaluate the effect of testosterone replacement
therapy on muscle pathology as assessed by muscle
MRI
 Evaluate the effect of testosterone replacement
therapy on bone mineral density and body
composition
Methods
Trial design and setting
This is a single-centre, prospective trial investigating the
clinical outcomes of pubertal induction with an incre-
mental regimen of intramuscular testosterone replace-
ment therapy in adolescents with DMD and delayed
puberty. The trial is being conducted at the Clinical
Research Facility, Royal Victoria Infirmary in Newcastle
upon Tyne, UK.
Study population
Potential participants will be identified during routine
follow-up appointments by clinicians from the John Wal-
ton Muscular Dystrophy Research Centre in Newcastle.
Potentially eligible subjects and their parent(s)/guardian(s)
(with legal authority to consent on behalf of the child) will
be invited to attend an initial screening visit.
Eligibility criteria
Inclusion criteria
 A molecular diagnosis of Duchenne Muscular
Dystrophy.
 Males aged between 12 and 17 years of age at time
of first dosing
 Pre-pubertal (Tanner stage 1, testicular volume < 4
mls, initial testosterone level of < 2.0 nmol/l)
 Subjects are receiving the standard of care for DMD
as recommended by the NorthStar UK [22] and
recently revised care guidelines [23].
 Patients are capable of sitting upright in a
wheelchair for at least an hour
 Patients have stable respiratory function. Artificial
ventilation with either Bipap/cPAP or tracheostomy
is not a contraindication to the study.
 Informed consent/assent signed by the patient (or
parent/guardian and assent if under 16 years of age)
Exclusion criteria
 Severe learning difficulties that would preclude them
from cooperating with examination.
 Anticipated surgery during the study period.
 Symptomatic cardiac failure.
 Participants/families who may have emotional or
psychological problems if recruited to a study
 Hypersensitivity to the active substance or to any of
the excipients, including arachis oil or derivatives
(including hypersensitivity and allergy to peanuts or
soya.)
 Any contra-indication to receiving an intramuscular
injection
 Any additional chronic disease that affects androgen
production
 Anti-coagulant therapy
 If participation in the study is not recommended in
the opinion of the investigators
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Intervention
Sustanon is widely used in the UK for androgen replace-
ment therapy and is routinely used, by prescription, to
treat pubertal delay. Sustanon 250 contains four esters
of testosterone with different durations of action:
1. Testosterone propionate 30mg/ml
2. Testosterone phenylpropionate 60mg/ml
3. Testosterone isocaproate 60mg/ml
4. Testosterone decanoate 100 mg/ml
(Equivalent to a total of 176 mg of Testosterone)
The esters are hydrolysed into the natural hormone
testosterone as soon as they enter the general
circulation. Sustanon 250 contains the excipients 1 ml
Arachis oil and benzyl alcohol. It is commercially
available from Merck Sharp & Dohme Limited. An
SmPC is available [24].
Sustanon 250 is administered by deep intramuscular
injection. Patients will follow a standard dose
incremental regimen for 2 years:
Sustanon 50 mg (0.2 ml) every 4 weeks for 12 weeks
Sustanon 100 mg (0.4 ml) every 4 weeks for 40 weeks
Sustanon 150 mg (0.6 ml) every 4 weeks for 24 weeks
Sustanon 250 mg (1 ml) every 4 weeks for 28 weeks
The first injection will be given to each subject in the
Clinical Research Facility. Subsequent injections will
either be given locally, at the subject’s General
Practitioners, or by local endocrine nurses, according to
individual preference and arrangements. A copy of the
suggested regimen will be given to all practitioners who
will be administering the testosterone; they will be asked
to document any reason for deviating from this protocol
on a form which is provided as part of the study
documents. Sustanon will be drawn up according to the
protocol and administered by a practitioner competent
in giving intramuscular injections. The medication will
be prescribed by a clinician according to the protocol,
and dispensed to the patient according to local
pharmacy policy.
The acute toxicity of Sustanon is low. If symptoms of
chronic overdose occur (such as polycythaemia and
priapism) then the drug should be discontinued or
temporarily paused. The practitioner will be encouraged
to discuss this with the Chief Investigator before
deciding on the most appropriate course of action, or to
record their action and reason for it. The study does not
foresee any safety issues, as the patients will follow a
standard incremental regimen and undergo assessments
consistent with those used in routine clinical practice.
Assessment of compliance
Each participant will have an injection record to fill in
the date and dose of each injection given. Where
feasible, study visits will coincide with routine clinical
follow-up, to enhance the likelihood of good compliance.
Visit windows of +/− 14 days should ensure visit attend-
ance; non-attendance for study visits will prompt
follow-up by telephone by the study investigator.
Discussion
Study procedures
Baseline assessments & data
If a subject is confirmed to have pubertal delay at
screening, he will be asked to return for a baseline visit.
At the baseline visit, he will be enrolled in the study
(Table 1). Only one patient failed screening, as they had
recently stopped their GC and were already peri-pubertal.
The following tests will be carried out:
 Physical examination and vital signs (including
height, weight, blood pressure, pulse)
 Medical history (including current medications,
vitamins and supplements)
 Blood sample for routine laboratory tests, blood
hormone levels, vitamin D and bone markers.
 Urine sample collection for analysis of bone
markers.
 Motor skills test (jumping, hopping, time to stand
from lying)
 Standard assessments of muscle strength, function
and range of movement
 The North Star Ambulatory Assessment including
six-minute walk test (6MWT) if subject can walk. If
subject is unable to walk unaided, he will be asked to
do the Performance of the Upper Limb (PUL) instead
 Physiotherapy assessment and advice
 Lung capacity test.
 Full-body DXXA scan for bone and muscle mass
(part of routine care)
 X-ray of wrist to give information on growth and
physical development (part of routine endocrine
care for delayed puberty)
 Heart function tests – electrocardiogram and
echocardiogram (part of routine care)
 Muscle MRI of arm and legs.
 Quality of Life questionnaire completion (PedsQL
questionnaires).
 Treatment Satisfaction for Medication questionnaire
completion.
 Semi-structured interviews (approx. 1 h)
Subsequent trial assessments
Once the baseline visit is completed and he has received
his first testosterone injection, every subject will be
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Table 1 Schedule of Events
Screening Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10
0
weeks
(+/−
14 days)
12
weeks
(+/−
14 days)
24–28
weeks
(+/−
14 days)
40
weeks
(+/−
14 days)
52
weeks
(+/−
14 days)
64
weeks
(+/−
14 days)
76–80
weeks
(+/−
14 days)
92
weeks
(+/−
14 days)
104
weeks
(+/−
14 days)
116
weeks
(+/−
14 days)
Clinic based evaluations
Informed consent X
Inclusion criteria X
Exclusion criteria X
Demography X
Medical history X X
Ability to comply with study evaluations X
Height X X X X X X X X X X
Weight X X X X X X X X X X
BP and other vital signs X X X X X X X X X X
Skin examination X X X X X X X X X
Pubertal examination X X X X X X
General physical examination X X X X X
Details of concomitant meds X X X X X X X X X
Details of Adverse Events X X X X X X X X X
Urine and blood tests
Urine for bone turnover markers/steroid
profile
X X X X X
Blood for haematology/chemistry X X X X X
Blood for testosterone, LH, FSH levels X X X X X X X X X X X
Blood for other hormone levels X X X
Blood for lipid profile X X X
Blood for 25-OH-D X X X X X
Blood for Ca/bone turnover markers X X X
Optional blood sample for Biobank X X X
Functional assessments
Respiratory function (FVC) X X X X X
NSAA and/ or PUL X X X X X
Timed and graded functional tests X X X X X
Muscle strength/ROM X X X X X
6 MWT X X X X X
Questionnaire assessments
TSQM X X X X X
PEDSQoL – parent X X X X X
PEDSQoL – child X X X X X
Semi-structured interview X X
Investigations
DXA X X X
Muscle MRI X X X
Echo X X X
ECG X X X
Wrist X-ray X X
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asked to return to either our centre or his local doctor
every 4 weeks for further injections, see also Fig. 1. Every
24–28 weeks, he will also have a follow-up visit at the
same time. The evaluations in this study will be carried
out as part of standard care for Duchenne Muscular
Dystrophy but will also be part of the study protocol and
follow-up. Both medical care and research will be carried
out at the same visit.
At each 4-weekly visit, the dosage of the testosterone
may be increased depending on the regimen. This is
the normal way to give testosterone to boys with pu-
bertal delay, to try and match what the body would
normally do, as closely as possible. If a subject expe-
riences side effects due to the study drug, this will be
documented and the study doctor may decide to
interrupt or reduce the testosterone dose that he is
receiving. Where possible, testosterone injections will
also be given at study visits, to minimise inconveni-
ence to participants.
12 weekly follow-up visits at 12, 40, 64 and 92 weeks: (at
CRF or with local doctor)
 Testosterone level
 Pulse and blood pressure, skin examination
 Concomitant medications and adverse events
recorded
24–28 weekly follow-up visits at 24–28, 52, 76–80, and
104 weeks (at CRF/great north children’s hospital)
 Blood and urine samples
 Pulse and blood pressure
 Concomitant medications and adverse events
recorded
 General and pubertal examination
 Same physiotherapy assessment and breathing tests
as at baseline
 Quality of Life questionnaire completion
Fig. 1 Testosterone study flowchart
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 Treatment Satisfaction for Medication
Questionnaire
52-week follow-up visit and 104 week visit (at CRF/MRI
centre)
In addition to those at 24–28 weeks, the following tests
will also be carried out:
 Muscle MRI
 Blood sample for routine laboratory tests, Vitamin D
levels and bone markers
 Urine sample collection for analysis of bone markers
 Full-body DEXA scan (x-ray) for bone and muscle
mass
 Echocardiogram and electrocardiogram
At the 104-week follow-up only, in addition to the above
 X-ray of wrist
 Semi-structured questionnaire
116-week final visit
Final blood test to check testosterone level, 3 months
after last injection.
Data collection will comprise:
Demographic data
Information will be collected regarding past medical
history, social history, family history (including family
history of pubertal delay), concomitant medications,
allergies and hospital admissions.
Treatment satisfaction questionnaire for medication (TSQM)
The quantitative primary outcome measure will be a
patient reported questionnaire validated to assess
subject/parent global satisfaction with treatment, known
as the Treatment Satisfaction Questionnaire for
Medication (TSQM), version 1.4 The TSQM is a
self-administered questionnaire that will be used at base-
line and every 6months thereafter. It is a 14-item instru-
ment, yielding four subscale scores: global satisfaction,
effectiveness, adverse events and convenience and has
been validated for adults with chronic disease [25]. The
total score from this will be the primary outcome meas-
ure to assess tolerability of testosterone given by intra-
muscular injection for the induction of pubertal delay.
Self-report questionnaires are vital as there is a docu-
mented poor correlation between the perceived health
related quality of life of adolescents with DMD and the
views of their parents. Data has shown that parents
grossly underestimate perception of son’s happiness and
of perceived support from social networks [26]. The par-
ticipants will complete questionnaires, with help from
their parents if required.
Semi-structured interviews
The semi-structured interviews will be recorded and used
to allow triangulation of the data obtained from the quanti-
tative components and gain greater insight into the sub-
jects’ views on the use of testosterone therapy. A topic
guide will be used, but the individual interviews will be
guided by the responses. In particular, we hope to explore
the boy’s ideas, concerns and expectations prior to testos-
terone therapy and discover whether these have been met
by their trial regimen. Experienced and suitably trained
members of the study team will carry out the interviews.
Coding and thematic analysis will be used. Semi-structured
interviews were felt to be the most suitable format as sev-
eral sensitive and potentially embarrassing issues are likely
to be explored, which would not be suitable for discussion
in a group setting. A semi-structured approach will be used
to allow the boy’s the freedom to steer the conversation
whilst still obtaining specific information regarding the
boy’s attitude to testosterone therapy.
Vital signs
Vital signs will be recorded at screening, baseline and
every subsequent visit to the CRF. These will consist of
height, weight, BMI (calculated), blood pressure and
pulse rate (beats per minute).
Standing height will be measured using a recently
calibrated stadiometer. Subjects who are unable to stand
with heels flat in an upright position due to Achilles tendon
contractures will be measured with both standing height
and ulna length. If the subject loses standing ability over
the duration of the trial, ulna length only will be measured.
Functional motor assessments
Physiotherapy assessments will be carried out at 6
monthly intervals, as in routine clinical practice. The
Performance of the Upper Limb (PUL 1.3) for DMD will
be performed on all subjects. This is a measure of upper
limb motor performance and its development and
reliability have been reported [27]. North Star Ambulatory
Assessment (NSAA) will also be used on the ambulant
DMD subjects. It is a robust and well validated measure of
ambulatory motor performance [28] which reflects
activities of daily living such as walking, standing up from
a chair, climbing a step, hopping, running and jumping. If
a child loses the ability to walk independently during the
study period, then only PUL will be used.
Timed and graded functional tests
Validated timed tests for the assessment of DMD will be
performed. These comprise:
1. Rise from floor (within NSAA)
2. 10 m walk/run (within NSAA)
3. Stairs climb and descend
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4. 6-min walk test
Assessments of muscle strength and range of movement
Standard assessments of muscle strength, function and
range of movement will be performed by trained, highly
experienced physiotherapists:
1. Knee flexion and extension
2. Elbow flexion and extension
3. Shoulder abduction
4. Grip strength
5. Assessment of workable reach space using Kinect
Spirometry (FVC, FEV1, peak cough flow)
Spirometry will be used to assess lung function and
strength of respiratory function. If the patient is on
non-invasive ventilation, the home ventilation team will
also review them. Spirometry is routinely performed
6-monthly, during outpatient clinic appointments. This
data will be collected to ensure that testosterone does
not have an adverse effect on respiratory function.
Dual X-ray absorptiometry (DXA)
A DXA scan will be performed yearly to assess lean
versus total body mass and to enable calculation of bone
mineral density, adjusted for age, size and gender.
Adjusted z-scores of lumbar spine and total body (minus
head) will be recorded. This is routine clinical care in
DMD patients who are receiving GC therapy.
Echocardiogram (echo) and electrocardiograph (ECG)
An echo and ECG will be carried out as standard
practise at yearly intervals and reviewed by a consultant
paediatric cardiologist. This data will be collected to
ensure that testosterone does not have an adverse effect
on cardiac function.
Laboratory assessments
As part of routine care within the endocrine assessment
for delayed puberty, the following assessments will also
be carried out at baseline and 12 weekly intervals:
 Testosterone, luteinizing hormone, follicle-
stimulating hormone.
Additional blood and urine tests will be carried out at
baseline and at 6-monthly intervals:
 Blood tests
1) Full blood count with differential, ferritin, urea and
electrolytes, thyroid function tests, liver function
tests, creatine kinase, calcium, magnesium,
parathyroid hormone, 25-OHD, total and
differential cholesterol levels, triglycerides, fasting
glucose and insulin.
2) Prolactin, growth hormone, insulin-like growth
factor-1, cortisol, ACTH, leptin, bone-specific alka-
line phosphatase, beta crosslaps, osteocalcin, P1NP,
RANKL, osteoprotegrin, sclerostin. These are op-
tional bloods, which will be taken if the patient con-
sents, from the same blood draw as the routine
haematology and biochemistry bloods. The option
to take an additional sample of blood for storage in
the BioBank will also be offered.
 Urine calcium/creatinine ratio
Pubertal staging
 Bone age will be assessed at baseline and at study
endpoint, using an Xray of the left wrist and the
‘Greulich and Pyle’ method [29].
 Testicular size will be assessed using a Prader
orchidometer.
 Pubertal staging will be assessed using the validated
Tanner Staging criteria [30]. If the subject refuses to
allow the assessor to undertake pubertal staging, the
Tanner criteria will be offered on a chart for self-
validation.
PedsQL self-report questionnaire
Quality of life will be measured using the PedsQL
questionnaire [31]. This will be administered at baseline
and then at 6-monthly intervals to the subject them-
selves and also to their parent/guardian. The Generic
Core Scale will be completed first and then the Neuro-
muscular Module.
Muscle MRI
Muscle MRI of the upper and lower limbs will be
carried out at baseline, 52 weeks of follow-up and at the
end of the study period. Scans will be carried out ac-
cording to a standard protocol (see Additional file 1). If
patients are unable to comply, their data will still be col-
lected for other components of the trial.
Statistical methods
Analysis of the primary outcome measure
This is an observational study designed to investigate
the effect of testosterone on boys with DMD for the first
time. The outcome measures have been chosen
according to their clinical validity and importance on
patient-reported, rather than parent-reported, measures.
A 2-year follow up period has been chosen, as this is a
practical time frame in which testosterone replacement
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therapy would usually act to trigger the natural pubertal
process.
There are no previous studies and background data is
limited hence formal power calculations are not
possible. As such, formal hypothesis testing will not be
carried out due to a probable lack of power. Statistical
analyses will be based on descriptive statistics. Quality of
life scores will be calculated according to validated
scoring systems accounting for missing items.
Analysis will be performed on an intention-to-treat
basis, using STATA version 13.0 [32]. Per protocol ana-
lyses may be carried out to inform future trial design.
Analysis of secondary outcome measures
Exploratory regression models will be used to investigate
and quantify the relationship between testosterone levels
at 104 weeks and important pre-specified clinical predic-
tors and treatment, whilst accounting for stratification
factors at randomisation. Results will be presented de-
scriptively as parameter estimates (with associated confi-
dence intervals).
Data from the semi-structured interviews will be ana-
lysed thematically. Two experienced qualitative re-
searchers will code and analyse the emergent themes, to
enable triangulation of data.
Interim analyses and criteria for the premature termination
of the trial
The trial may be prematurely discontinued on the basis
of new safety information, or for other reasons given by
the Data Monitoring Committee and/or Trial Steering
Committee, Sponsor, regulatory authority or ethics
committee concerned.
Statistical size calculations
We initially chose to recruit 20 boys with DMD as this
represented a realistic recruitment target from the local
population of boys with DMD and pubertal delay who
are not already enrolled in a clinical trial. The target
recruitment figure of 20 was chosen pragmatically based
upon what was considered feasible and realistic given
the rare nature of the condition and the expected
availability of eligible patients within the recruitment
period and the recruitment area. As such formal
statistical power calculations are not possible. This was
discussed and agreed by the statistician within the
Clinical Trials Unit. The availability of eligible
participants within the said timeframe proved to be
lower than anticipated, with the final recruitment
achieved at 15 participants. This final recruitment figure
was discussed within the Steering Committee where it
was confirmed that this downward revision has no
impact upon the data analysis in view of the original
target not being statistically powered and that no formal
hypothesis testing is planned due to this lack of power.
The amended sample size was submitted to the Ethics
Committee and approved as a minor amendment.
As an observational study, the aim of this trial is to
provide the evidence of efficacy and acceptability of
testosterone replacement therapy, on which to enable
power calculations for a larger multi-centre trial.
The decision to continue with further research would
be based on:
Evidence of acceptability and clinical effectiveness of
testosterone treatment according to:
i) Feedback in qualitative interviews
ii) Scores from the Treatment Satisfaction for
Medication Questionnaires
iii) Changes in secondary outcome measures
Data monitoring and reporting
Adverse events and concomitant medications will be
assessed and documented at baseline and at all of the
subsequent trial visits. A structured record of adverse
events and reactions will be made in the database so
that tolerability can be accurately assessed by the trial
team.
A trial management group, trial steering committee
and data monitoring committee have been set up and
will oversee the trial and all associated regulatory
matters. A trial monitoring plan has been developed and
agreed by the trial management group, trial steering
committee and sponsor. On-site monitoring visits will
be conducted in accordance with the monitoring plan.
The data monitoring committee is independent from the
sponsor and does not have any competing interests.
The trial will be conducted in accordance with the
Medicines for Human Use (Clinical Trials) Regulations
2004 and subsequent amendments. All parties must
abide by these regulations and the ICH GCP guidelines.
Clinical Trial Authorisation was obtained from the
MHRA prior to the start of the trial and the trial Sponsor
will notify the MHRA of any substantial amendments that
require review. These substantial amendments will not be
implemented until the MHRA have issued an acceptance
of the amendment. The Development Safety Update
Report will be submitted to the MHRA by the CI on an
annual basis until the end of the trial.
The procedures are compliant with the Ionising
Radiation (Medical Exposure) Regulations and appropriate
review by a Medical Physics Expert and Clinical Radiation
Expert has been undertaken.
Withdrawal criteria
Participants have the right to withdraw from the trial at
any time without having to give a reason. Investigator
sites should try to ascertain the reason for withdrawal
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and document this reason within the Case Report Form
and participant’s medical notes. The investigator also has
the right to withdraw patients from the study drug in
the event of inter-current illness, side effects, serious ad-
verse events, suspected unexpected serious adverse reac-
tions, administrative reasons or other reasons. Should a
patient stop taking testosterone through their own
choice, efforts will be made to continue to obtain
follow-up data, with the permission of the patient.
The Investigator may discontinue a participant from
the trial at any time if the Investigator considers it
necessary for any reason including:
 Symptomatic deterioration
 Unacceptable toxicity
 Participant withdrawal of consent
 Significant protocol deviation or non-compliance
 Investigator’s discretion that it is in the best interest
of the participant to withdraw
 An adverse event that requires discontinuation of
the trial medication or renders the participant
unable to continue in the trial
 Termination of the clinical trial by the sponsor
Participants who withdraw from the trial will not be
replaced.
Participant timeline
The study opened for recruitment in December 2015
and the first patient was consented in the same month.
The study is now closed for recruitment (closed
December 2016) as 15 participants were recruited,
which is consistent with the amended target and the
patients are currently completing the 27month study
period. The last patient will complete their last study
visit in February 2019. No data from the study has been
analysed yet. Discussions are currently underway to seek
funding to run an observational extension study,
enabling the same cohort of patients to be followed up
for a further two years.
Data handling
Data collected on paper Case Report Forms will be
entered onto a secure validated clinical data
management system. A unique study identifier will be
used to identify participants on case report forms. Data
will be handled, computerised and stored in accordance
with the Data Protection Act 1998. No participant
identifiable data will leave the study site. Paper copies of
all study related laboratory results will be annotated,
signed and dated and filed in the medical notes/records.
The quality and retention of study data will be the
responsibility of the Chief Investigator. All study data
will be retained in accordance with the latest Directive
on GCP (2005/28/EC) and local policy.
Clinical information will not be released without the
written permission of the participant, except as necessary
for monitoring and auditing by the Sponsor, its designee,
Regulatory Authorities, the Data Monitoring Committee
(DMC) or the REC. Secure anonymised electronic data
may however be released to the Study Statistician for
analysis. The PI and study site staff involved with this
study may not disclose or use for any purpose other than
performance of the study, any data, record, or other
unpublished, confidential information disclosed to those
individuals for the purpose of the study. Prior written
agreement from the Sponsor or its designee must be
obtained for the disclosure of any said confidential
information to other parties.
Protocol version and amendments
This study protocol is based on version 1.2 of the trial
protocol. The first minor amendment was made to
address the change in recruitment target from 20
participants to 15. The second minor amendment
reflected a small change in the SmPC.
Dissemination
It is planned to publish this study in peer review articles
and to present data at national and international
meetings. Results of the study will also be reported to
the Sponsor and Funder, and will be available on their
web site. The Trial Steering Committee and Funder will
review all manuscripts, abstracts or other modes of
presentation prior to submission. Individuals will not be
identified from any study report. Participants will be
informed about their treatment and their contribution to
the study at the end of the study, including a lay
summary of the results.
Additional file
Additional file 1: MRI Standard Operating Procedure for Testosterone in
DMD study. (DOCX 104 kb)
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